Barinthus Biotherapeutics PLC BRNS.OQ, BRNS.O is expected to show no change in quarterly revenue when it reports results on November 7 (estimated) for the period ending September 30 2024
LSEG's mean analyst estimate for Barinthus Biotherapeutics PLC is for a loss of 44 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Barinthus Biotherapeutics PLC is 7.00, above its last closing price of $1.34.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -0.41 | -0.41 | -0.43 | Missed | -4 |
Mar. 31 2024 | -0.54 | -0.54 | -0.40 | Beat | 26.5 |
Dec. 31 2023 | -0.40 | -0.50 | -0.45 | Beat | 9.9 |
Sep. 30 2023 | -0.53 | -0.53 | -0.37 | Beat | 30.2 |
Jun. 30 2023 | -0.54 | -0.55 | -0.62 | Missed | -13.3 |
Mar. 31 2023 | -0.47 | -0.50 | -0.48 | Beat | 4.6 |
Jan. 1 0001 | -0.42 | -0.57 | Missed | -33.4 | |
Sep. 30 2022 | -0.35 | -0.33 | 0.22 | Beat | 166.7 |
This summary was machine generated November 6 at 05:27 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。